Næste

Automatisk afspilning

Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma

1 Visninger • 07/18/23
Del
Indlejre
administrator
administrator
Abonnenter
0

William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning